Zulfa Omer, MD, discusses BTK degraders, how they differentiate from BTK inhibitors, and their remaining unknowns for chronic lymphocytic leukemia.
Zulfa Omer, MD
Advertisement
Zulfa Omer, MD, is an assistant professor of Clinical in the Department of Internal Medicine at the University of Cincinnati College of Medicine.
Articles by Zulfa Omer, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Zanidatamab-Based Regimens for First-Line HER2+ Locally Advanced or Metastatic Gastric Cancer
2
FDA Grants Fast Track Designation to Pan-RAS Molecular Glue ERAS-0015 for Metastatic Pancreatic Adenocarcinoma
3
FDA Grants Priority Review to Dostarlimab for dMMR/MSI-H Locally Advanced Rectal Cancer
4
MOMENTUM Trial Aims to Add Further Evidence for Cemsidomide in R/R Myeloma
5